Leveraging academic medicine into innovative therapies through partnerships

Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development

Clinical Trials

Phase 1 biomarker data shows improvement of safety profiles of vamorolone over prednisolone for adrenal suppression, bone turnover, insulin resistance, and immune suppression. Learn more >

About vamorolone

Vamorolone enrollment in Phase 2a opens at Duke University; first DMD subjects enrolled.

Learn More


microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.

Learn More


– Winner to be announced during 2018 BioHealth Capital Region Forum –

ROCKVILLE, MARYLAND, April 12, 2018 – Five companies have been selected to present to a panel of investor judges and an audience of industry leaders during the 2018

Learn More